Author Title Type [ Year(Asc)]
Filters: First Letter Of Title is T  [Clear All Filters]
Vagnozzi RJ, McKinsey TA. T cell immunotherapy for cardiac fibrosis: mRNA starts the CAR. Cell Stem Cell. 2022;29(3):352-354.
Zuo L, Kuo W-T, Cao F, Chanez-Paredes SD, Zeve D, Mannam P, Jean-François L, Day A, W Graham V, Sweat YY, et al. Tacrolimus-binding protein FKBP8 directs myosin light chain kinase-dependent barrier regulation and is a potential therapeutic target in Crohn's disease. Gut. 2022.
Ancel J, Guecamburu M, V Da Silva M, Schilfarth P, Boyer L, Pilette C, Martin C, Devillier P, Berger P, Zysman M, et al. [Take-home messages from the COPD 2021 biennial of the French Society of Respiratory Diseases. Understanding to so as to better innovate]. Rev Mal Respir. 2022.
Pavlovich MJ. Taking the guesswork out of journal submission with Community Review. Cell Stem Cell. 2022;29(5):663-666.
Birnbaum F, Eguchi A, Pardon G, C Y Chang A, Blau HM. Tamoxifen treatment ameliorates contractile dysfunction of Duchenne muscular dystrophy stem cell-derived cardiomyocytes on bioengineered substrates. NPJ Regen Med. 2022;7(1):19.
Katsanos D, Barkoulas M. Targeted DamID in reveals a direct role for LIN-22 and NHR-25 in antagonizing the epidermal stem cell fate. Sci Adv. 2022;8(5):eabk3141.
Pourradi NMohammad A, Babaei H, Hamishehkar H, Baradaran B, Shokouhi-Gogani B, Shanehbandi D, Ghorbani M, Azarmi Y. Targeted delivery of doxorubicin by Thermo/pH-responsive magnetic nanoparticles in a rat model of breast cancer. Toxicol Appl Pharmacol. 2022:116036.
Cruz AFilipa, Fonseca NA, Malheiro ARita, Melo JB, Gaspar MManuela, Fernandes R, Moura V, Simões S, Moreira JNuno. Targeted liposomal doxorubicin/ceramides combinations: the importance to assess the nature of drug interaction beyond bulk tumor cells. Eur J Pharm Biopharm. 2022.
Ali N, Sharma AArunkumar, de Rezende ACarolina P, Otegbeye F, Latif BMuhammad, Kerbauy MNassif, Cooper BW, Sanchez G, Metheny L, Bal SK, et al. Targeted Marrow Irradiation Intensification of Reduced Intensity Fludarabine/Busulfan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2022.
Huang T, Zhang T, Gao J. Targeted mitochondrial delivery: A therapeutic new era for disease treatment. J Control Release. 2022.
Narayan N, Huntly BJP. Targeting AML at the intersection of epigenetics and signaling. Sci Signal. 2022;15(730):eabo0059.
Zattoni IFatima, Delabio LCarani, Dutra Jde Paula, Kita DHenrique, Scheiffer G, Hembecker M, Pereira Gda Silva, Moure VRotuno, Valdameri G. Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators. Eur J Med Chem. 2022;237:114346.
Funasaki S, Mehanna S, Ma W, Nishizawa H, Kamikubo Y, Sugiyama H, Ikeda S, Motoshima T, Hasumi H, W Linehan M, et al. Targeting chemoresistance in Xp11.2 translocation renal cell carcinoma using a novel polyamide-chlorambucil conjugate. Cancer Sci. 2022.
Zhu G-Q, Wang Y, Wang B, Liu W-R, Dong S-S, Chen E-B, Cai J-L, Wan J-L, Du J-X, Song L-N, et al. Targeting HNRNPM inhibits cancer stemness and enhances antitumor immunity in Wnt-activated hepatocellular carcinoma. Cell Mol Gastroenterol Hepatol. 2022.
Zangari B, Tsuji T, Matsuzaki J, Mohammadpour H, Eppolito C, Battaglia S, Ito F, Chodon T, Koya R, McGray AJRobert, et al. Tcf-1 protects anti-tumor TCR-engineered CD8 T-cells from GzmB mediated self-destruction. Cancer Immunol Immunother. 2022.
Klatt MG, Dao T, Yang Z, Liu J, Mun SSoo, Dacek MM, Luo H, Gardner TJ, Bourne CM, Peraro L, et al. A TCR Mimic CAR T Cell Specific for NDC80 Is Broadly Reactive With Solid Tumors and Hematological Malignancies. Blood. 2022.
Tsilifis C, Lum SHan, Nademi Z, Hambleton S, Flood TJ, Williams EJ, Owens S, Abinun M, Cant AJ, Slatter MA, et al. TCRαβ-Depleted Haploidentical Grafts Are a Safe Alternative to HLA-Matched Unrelated Donor Stem Cell Transplants for Infants with Severe Combined Immunodeficiency. J Clin Immunol. 2022.
Serapicos P, Kim C, Barros SLeite, Jordão IMaria Bast, Hiyane MIoshie, de Sousa LBarbosa, Zecchin VGottardell, Câmara NOlsen Sara, de Oliveira LAugusto. Tear Film Immunological Profile in Patients with Ocular Graft versus Host Disease. Ocul Immunol Inflamm. 2022:1-9.
Gok V, Tada H, Dogan MEnsar, Sari UAlakus, Aslan K, Ozcan A, Yilmaz E, Kardas F, Karakukcu M, Canatan H, et al. A teenager boy with a novel variant of Sitosterolemia presented with pancytopenia. Clin Chim Acta. 2022.
Gao X, Yu X, Zhang C, Wang Y, Sun Y, Sun H, Zhang H, Shi Y, He X. Telomeres and Mitochondrial Metabolism: Implications for Cellular Senescence and Age-related Diseases. Stem Cell Rev Rep. 2022.
Coombs EJ, Felice RN, Clavel J, Park T, Bennion RF, Churchill M, Geisler JH, Beatty B, Goswami A. The tempo of cetacean cranial evolution. Curr Biol. 2022.
Karimi H, Marefat H, Khanbagi M, Kalafatis C, Modarres MHadi, Vahabi Z, Khaligh-Razavi S-M. Temporal dynamics of animacy categorization in the brain of patients with mild cognitive impairment. PLoS One. 2022;17(2):e0264058.
Sinniah E, Wu Z, Shen S, Naval-Sanchez M, Chen X, Lim J, Helfer A, Iyer A, Tng J, Lucke AJ, et al. Temporal perturbation of histone deacetylase activity reveals a requirement for HDAC1-3 in mesendoderm cell differentiation. Cell Rep. 2022;39(7):110818.
McKenna SL, Ehsanian R, Liu CY, Steinberg GK, Jones L, Lebkowski JS, Wirth E, Fessler RG. Ten-year safety of pluripotent stem cell transplantation in acute thoracic spinal cord injury. J Neurosurg Spine. 2022:1-10.
Miki S, Koga T, Mckinney AM, Parisian AD, Tadokoro T, Vadla R, Masala M, Hevner RF, Costello JF, Furnari F. TERT promoter C228T mutation in neural progenitors confers growth advantage following telomere shortening in vivo. Neuro Oncol. 2022.